M1366 – Focusing on women's health mips value pathway

Long description

Focusing on women's health mips value pathway

Short description

Focus on women's health mvp

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2024

Last change

January 1, 2024 – No change

Nearby M codes

• M1358 – Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment
• M1359 – Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained
• M1360 – Suicidal ideation and/or behavior symptoms based on the c-ssrs
• M1361 – Suicide risk based on their clinician's evaluation or a clinician-rated tool
• M1362 – Patients who died during the measurement period
• M1363 – Patients who did not have a follow-up assessment within 120 days of the index assessment
• M1364 – Calculated 10-year ascvd risk score of >= 20 percent during the performance period
• M1365 – Patient encounter during the performance period with hospice and palliative care specialty code 17
• M1367 – Quality care for the treatment of ear, nose, and throat disorders mips value pathway
• M1368 – Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway
• M1369 – Quality care in mental health and substance use disorders mips value pathway
• M1370 – Rehabilitative support for musculoskeletal care mips value pathway
• M1371 – Most recent glycemic status assessment (hba1c or gmi) level < 7.0%
• M1372 – Most recent glycemic status assessment (hba1c or gmi) level >= 7.0% and < 8.0%
• M1373 – Most recent glycemic status assessment (hba1c or gmi) level >= 8.0% and <= 9.0%
• M1374 – An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period